This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...
This combination of growth and value stocks has the potential to outperform the broader market in 2025 (and beyond).
Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...
Phase 2b study confirms duvakitug's efficacy in ulcerative colitis and Crohn’s disease, advancing towards Phase 3 development.Quiver AI SummaryTeva Pharmaceuticals and Sanofi announced that their Phase...
Investors are now eyeing duvakitug’s potential to become a significant revenue driver for both companies, especially as there is currently no cure for IBD.
Teva has agreed to divest its Japanese business, Teva-Takeda, to JKI, focusing on innovative medicines.Quiver AI SummaryTeva Pharmaceutical Industries Ltd. has announced an agreement with JKI Co., Ltd.,...
AJOVY® (fremanezumab) reduces migraine days in children, showing efficacy and safety in a Phase 3 study.Quiver AI SummaryTeva Pharmaceutical Industries has announced positive results from its Phase 3...
A tiny company in a fast-growing industry is a recipe for millionaire-making potential. And with shares up by a whopping 347% year to date as of this writing, SoundHound AI (NASDAQ: SOUN) has been a top...
Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well as sales....
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.